Most-Downgraded StocksMost-DowngradedNASDAQ:APLS Apellis Pharmaceuticals (APLS) Stock Forecast, Price & News $38.94 +1.80 (+4.85%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$36.32▼$39.6450-Day Range$23.65▼$48.5352-Week Range$19.83▼$94.75Volume2.14 million shsAverage Volume2.80 million shsMarket Capitalization$4.58 billionP/E RatioN/ADividend YieldN/APrice Target$66.13 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Apellis Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside69.9% Upside$66.13 Price TargetShort InterestBearish11.56% of Shares Sold ShortDividend StrengthN/ASustainability-1.27Upright™ Environmental ScoreNews Sentiment0.63Based on 12 Articles This WeekInsider TradingSelling Shares$10.57 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.89) to ($2.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.58 out of 5 starsMedical Sector138th out of 976 stocksPharmaceutical Preparations Industry43rd out of 447 stocks 4.4 Analyst's Opinion Consensus RatingApellis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 9 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $66.13, Apellis Pharmaceuticals has a forecasted upside of 69.9% from its current price of $38.94.Amount of Analyst CoverageApellis Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.56% of the outstanding shares of Apellis Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverApellis Pharmaceuticals has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Apellis Pharmaceuticals has recently increased by 10.56%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldApellis Pharmaceuticals does not currently pay a dividend.Dividend GrowthApellis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreApellis Pharmaceuticals has received a 67.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for deficiency diseases", "Pegcetacoplan", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Apellis Pharmaceuticals is -1.27. Previous Next 2.6 News and Social Media Coverage News SentimentApellis Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Apellis Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 33 people have searched for APLS on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat Follows16 people have added Apellis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,568,621.00 in company stock.Percentage Held by InsidersOnly 7.50% of the stock of Apellis Pharmaceuticals is held by insiders.Percentage Held by Institutions90.43% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($4.89) to ($2.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Apellis Pharmaceuticals is -6.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Apellis Pharmaceuticals is -6.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApellis Pharmaceuticals has a P/B Ratio of 25.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Apellis Pharmaceuticals (NASDAQ:APLS) StockApellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Read More APLS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APLS Stock News HeadlinesOctober 2, 2023 | markets.businessinsider.comApellis Pharmaceuticals Announces FDA Approval Of EMPAVELI Injector - Quick FactsOctober 2, 2023 | finance.yahoo.comApellis Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-AdministrationOctober 3, 2023 | Stansberry Research (Ad)Investing Legend Warns: NVIDIA is a "Delusion"Irrational investment in this tech giant may have made it “too big to succeed” says this renowned expert. Read this before you buy shares.October 2, 2023 | americanbankingnews.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Sees Large Growth in Short InterestSeptember 29, 2023 | tmcnet.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)September 29, 2023 | markets.businessinsider.comDEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $500,000 to Contact the FirmSeptember 28, 2023 | barrons.comMONDAY INVESTOR DEADLINE: Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 28, 2023 | americanbankingnews.comApellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 3, 2023 | Oxford Club (Ad)The Ultimate Passive Income PlayThe #1 income play for 2023 is NOT a stock, bond or private company... Rather, it's a little-known alternative investment that could hand you big monthly income from oil and gas.September 27, 2023 | msn.comApellis Pharmaceuticals sinks amid new short reportSeptember 27, 2023 | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Receives Buy Rating from HC WainwrightSeptember 25, 2023 | stockhouse.comOCTOBER 2 DEADLINE: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSeptember 25, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and DENTSPLY SIRONA (XRAY)September 25, 2023 | finance.yahoo.comApellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023September 24, 2023 | prnewswire.comAPLS NOTICE: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 2 Deadline in Securities Class Action - APLSSeptember 24, 2023 | americanbankingnews.comApellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4% September 22, 2023 | benzinga.comApellis Pharmaceuticals Unusual Options Activity For September 22September 21, 2023 | markets.businessinsider.comRobert W. Baird Remains a Buy on Apellis Pharmaceuticals (APLS)September 20, 2023 | markets.businessinsider.comApellis Pharmaceuticals: Strong Competitive Positioning and Safety Confidence Reinforce Buy RatingSeptember 19, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Boston Scientific (BSX), Apellis Pharmaceuticals (APLS) and Healthequity (HQY)September 19, 2023 | barrons.comS&P 500 Futures Climb in Premarket Trading; Apellis Pharmaceuticals, Liberty Media SiriusXM A LeadSeptember 19, 2023 | proactiveinvestors.comApellis Pharmaceuticals gets schadenfreude lift as rival trial failsSeptember 19, 2023 | proactiveinvestors.comApellis Pharmaceuticals sees schadenfreude stock boost as rival trial failsSeptember 19, 2023 | msn.comApellis spikes as Astellas posts long-term data for rival productSeptember 16, 2023 | markets.businessinsider.comROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - APLSSeptember 15, 2023 | msn.comWells Fargo ups Apellis to overweight, stock climbs 8%September 15, 2023 | msn.comWells Fargo Upgrades Apellis Pharmaceuticals (APLS)See More Headlines Receive APLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address APLS Company Calendar Last Earnings7/31/2023Today10/03/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APLS CUSIPN/A CIK1492422 Webwww.apellis.com Phone(617) 977-5700FaxN/AEmployees767Year Founded2009Price Target and Rating Average Stock Price Forecast$66.13 High Stock Price Forecast$141.00 Low Stock Price Forecast$29.00 Forecasted Upside/Downside+70.7%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($5.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-652,170,000.00 Net Margins-356.02% Pretax Margin-356.37% Return on Equity-212.82% Return on Assets-74.50% Debt Debt-to-Equity Ratio0.27 Current Ratio5.11 Quick Ratio4.52 Sales & Book Value Annual Sales$75.42 million Price / Sales60.49 Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book25.16Miscellaneous Outstanding Shares117,740,000Free Float108,907,000Market Cap$4.56 billion OptionableNot Optionable Beta1.10 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Cedric Francois M.D. (Age 51)Ph.D., Co-Founder, Pres, CEO & Director Comp: $1.2MDr. Pascal Deschatelets Ph.D. (Age 53)Co-Founder & Chief Scientific Officer Comp: $688.05kMr. Alec Machiels J.D. (Age 50)MBA, Co-Founder & Director Comp: $72.5kMr. Timothy E. Sullivan (Age 52)CFO & Treasurer Comp: $716.41kMr. David O. Watson Esq. (Age 50)J.D., Gen. Counsel Comp: $675.35kMr. Adam J. Townsend (Age 46)Chief Commercial Officer Comp: $701.61kMs. Nur Nicholson (Age 54)Chief Technical Operations Officer Mr. James G. Chopas CPA (Age 57)VP, Corp. Controller & Chief Accounting Officer Ms. Meredith KayaSr. VP, Investor Relations & Strategic Fin.Ms. Karen Lewis (Age 51)Chief People Officer More ExecutivesKey CompetitorsIntra-Cellular TherapiesNASDAQ:ITCIAlkermesNASDAQ:ALKSAscendis Pharma A/SNASDAQ:ASNDElanco Animal HealthNYSE:ELANOrganon & Co.NYSE:OGNView All CompetitorsInsiders & InstitutionsBarclays PLCBought 70,049 shares on 9/21/2023Ownership: 0.265%Alec MachielsSold 1,250 sharesTotal: $56,250.00 ($45.00/share)Nur NicholsonSold 20,350 sharesTotal: $900,894.50 ($44.27/share)Alec MachielsSold 1,250 sharesTotal: $56,675.00 ($45.34/share)Pascal DeschateletsSold 12,000 sharesTotal: $514,440.00 ($42.87/share)View All Insider TransactionsView All Institutional Transactions APLS Stock - Frequently Asked Questions Should I buy or sell Apellis Pharmaceuticals stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 5 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" APLS shares. View APLS analyst ratings or view top-rated stocks. What is Apellis Pharmaceuticals' stock price forecast for 2023? 15 Wall Street research analysts have issued twelve-month price targets for Apellis Pharmaceuticals' stock. Their APLS share price forecasts range from $29.00 to $141.00. On average, they expect the company's stock price to reach $66.13 in the next year. This suggests a possible upside of 70.7% from the stock's current price. View analysts price targets for APLS or view top-rated stocks among Wall Street analysts. How have APLS shares performed in 2023? Apellis Pharmaceuticals' stock was trading at $51.71 at the beginning of 2023. Since then, APLS stock has decreased by 25.1% and is now trading at $38.75. View the best growth stocks for 2023 here. Are investors shorting Apellis Pharmaceuticals? Apellis Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totaling 13,610,000 shares, an increase of 10.6% from the August 31st total of 12,310,000 shares. Based on an average daily volume of 4,730,000 shares, the short-interest ratio is presently 2.9 days. View Apellis Pharmaceuticals' Short Interest. When is Apellis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our APLS earnings forecast. How were Apellis Pharmaceuticals' earnings last quarter? Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced its earnings results on Monday, July, 31st. The company reported ($1.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.35) by $0.33. The business had revenue of $95 million for the quarter, compared to analyst estimates of $70.38 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 212.82% and a negative net margin of 356.02%. The business's quarterly revenue was up 482.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.46) earnings per share. What ETFs hold Apellis Pharmaceuticals' stock? ETFs with the largest weight of Apellis Pharmaceuticals (NASDAQ:APLS) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Jacob Forward ETF (JFWD), Vanguard Russell 2000 Growth ETF (VTWG), Principal Healthcare Innovators ETF (BTEC) and Vanguard Small-Cap Growth ETF (VBK).Harbor Health Care ETF (MEDI). What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO? 18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend. What other stocks do shareholders of Apellis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI). When did Apellis Pharmaceuticals IPO? (APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO. What is Apellis Pharmaceuticals' stock symbol? Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS." How do I buy shares of Apellis Pharmaceuticals? Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Apellis Pharmaceuticals' stock price today? One share of APLS stock can currently be purchased for approximately $38.75. How much money does Apellis Pharmaceuticals make? Apellis Pharmaceuticals (NASDAQ:APLS) has a market capitalization of $4.56 billion and generates $75.42 million in revenue each year. The company earns $-652,170,000.00 in net income (profit) each year or ($5.83) on an earnings per share basis. How many employees does Apellis Pharmaceuticals have? The company employs 767 workers across the globe. Does Apellis Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Apellis Pharmaceuticals: APL DEL Holdings II LLC, APL DEL Holdings LLC, APL PRG I Corp., APL Sales I LLC, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., Apellis MA Securities Inc., Apellis Netherlands B.V., Apellis Switzerland GmbH, Apellis U.K. Limited, and Potentia Pharmaceuticals.Read More How can I contact Apellis Pharmaceuticals? Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The official website for the company is www.apellis.com. The company can be reached via phone at (617) 977-5700 or via email at investors@apellis.com. This page (NASDAQ:APLS) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.